ReGenX grants AveXis global rights to use rAAV9 vectors in SMA therapies; deal expanded
Executive Summary
ReGenX Biosciences LLC granted fellow gene therapy firm AveXis Inc. exclusive worldwide rights--plus sublicensing rights--to use its NAV-based recombinant adeno-associated virus rh9 (rAAV9) vectors to develop treatments for spinal muscular atrophy (SMA).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice